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Abstract 
The treatment of chronic myeloid leukaemia (CML) requires quantitative polymerase chain 
reaction (qPCR) to monitor BCR-ABL1 in International Scale (IS). Some normal subjects were 
found to harbour BCR-ABL1. We performed a systematic review on normal subjects 
harbouring BCR-ABL1. A literature search was done on July 16, 2017 using EBSCOhost 
Research Databases interface and Western Pacific Region Index Medicus. Two authors selected 
the studies, extracted the data, and evaluated the quality of studies using the modified Appraisal 
Tool for Cross-Sectional Studies independently. The outcomes were prevalence, level of BCR-
ABL1IS, proportion, and time of progression to CML. The initial search returned 4,770 studies. 
Eleven studies, all having used convenient sampling, were included, with total of 1,360 subjects. 
Ten studies used qualitative PCR and one used qPCR (not IS). The mean prevalence of M-BCR 
was 5.9, 15.5, and 15.9% in cord blood/newborns/infants (CB/NB/I) (n = 170), children (n = 90), 
and adults (n = 454), respectively, while m-BCR was 15, 26.9, and 23.1% in CB/NB/I (n = 786), 
children (n = 67), and adults (n = 208), respectively. No study reported the proportion and time 
of progression to CML. Nine studies were graded as moderate quality, one study as poor quality, 
and one study as unacceptable. The result of the studies could neither be inferred to the general 
normal population nor compared. Follow-up data were scarce. 
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